Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients

Transplantation

Volumn 89, Issue 3, 2010, Pages 347-352

  Sharif, Adnan ^a,b   Ravindran, Vinod ^b   Dunseath, Gareth ^c   Luzio, Steve ^c   Owens, David R ^c   Baboolal, Keshwar ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Central obesity; Classifications; Insulin resistance; Metabolic syndrome; Pathophysiology; Transplantation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; WAIST HIP RATIO;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL, HDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MALE; METABOLIC SYNDROME X; OBESITY; PATIENT SELECTION; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 76649114678     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bd06d2     Document Type: Article

References (24)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595.
2. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiol-ogy: The role of adipose tissue. Nutr Metab Cardiovasc Dis 2007; 17: 125.
3. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978.
4. Balkau B, Valensi P, Eschwege E, et al. A review of the metabolic syndrome. Diabetes Metab 2007; 33: 405.
5. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433.
6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-A new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469.
7. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
8. Courivaud C, Kazory A, Simula-Faivre D, et al. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83: 1577.
9. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134.
10. Bergman RN, Prager R, Volund A, et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79: 790.
11. Steil GM, Murray J, Bergman RN, et al. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes 1994; 43: 1365.
12. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119(5 suppl 1): S10.
13. Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403.
14. Bayes B, Granada ML, Pastor MC, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416.
15. Armstrong KA, Hiremagalur B, Haluska BA, et al. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation 2005; 80: 937.
16. Lee J, Ma S, Heng D, et al. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 2007; 30: 343.
17. Reaven GM. The metabolic syndrome: Isthis diagnosis necessary? Am J Clin Nutr 2006; 83: 1237.
18. Kahn R, Buse J, Ferrannini E, et al; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: Time foracritical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289.
19. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403.
20. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
21. Oterdoom LH, de Vries AP, Gansevoort RT, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation 2007; 83: 29.
22. Boots JM, van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221.
23. Armstrong KA, Campbell SB, Hawley CM, et al. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005; 5: 2710.
24. Ducloux D, Kazory A, Simula-Faivre D, et al. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922.